Research publications | Alfred Health

Therapeutic drug monitoring in inflammatory bowel disease: too little too early?-comments on the American Gastroenterology Association Guideline

Su HY, Ward MG, Sparrow MP

(2017), Transl Gastroenterol Hepatol, 2, 113

DOI: 10.21037/tgh.2017.12.05

Is there a role for thioguanine therapy in IBD in 2017 and beyond?

Taylor KM, Ward MG, Blaker PA, Sparrow MP

(2017), Expert Rev Gastroenterol Hepatol, 11(5), 473-86

DOI: 10.1080/17474124.2017.1294062

Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies

Goel G, King T, Daveson AJ, Andrews JM, Krishnarajah J, Krause R, Brown GJE, Fogel R, Barish CF, Epstein R, Kinney TP, Miner PB Jr, Tye-Din JA, Girardin A, Taavela J, Popp A, Sidney J, Mâki M, Goldstein KE, Griffin PH, Wang S, Dzuris JL, Williams LJ, Sette A, Xavier RJ, Sollid LM, Jabri B, Anderson RP

(2017), Lancet Gastroenterol Hepatol, 2(7), 479-93

DOI: 10.1016/S2468-1253(17)30110-3

Adenoma recurrence after piecemeal colonic EMR is predictable: the Sydney EMR recurrence tool

Tate DJ, Desomer L, Klein A, Brown G, Hourigan LF, Lee EY, Moss A, Ormonde D, Raftopoulos S, Singh R, Williams SJ, Zanati S, Byth K, Bourke MJ

(2017), Gastrointest Endosc, 85(3), 647-56.e6

DOI: 10.1016/j.gie.2016.11.027

Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse

Aggarwal V, Day AS, Connor S, Leach ST, Brown G, Singh R, Friedman A, Zekry A, Craig PI

(2017), Gastrointest Endosc, 86(6), 1070-8

DOI: 10.1016/j.gie.2017.09.011

Hepatobiliary and pancreatic: hepatic and mesenteric aneurysms with biloma formation

Ling QA, Yo J, Gerstenmaier JF, Kemp W

(2017), J Gastroenterol Hepatol, 32(6), 1134

DOI: 10.1111/jgh.13765

Dementia, cognitive impairment and proton pump inhibitor therapy: a systematic review

Batchelor R, Gilmartin JF, Kemp W, Hopper I, Liew D

(2017), J Gastroenterol Hepatol, 32(8), 1426-35

DOI: 10.1111/jgh.13750

Hepatobiliary and pancreatic: rare vascular tumor following treatment for hepatitis C with direct-acting antivirals

Britto K, Cheung W, Cameron R, Roberts SK, Kemp W

(2017), J Gastroenterol Hepatol, 32(12), 1912

DOI: 10.1111/jgh.13916

Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: a large multicentre cohort study

Mgaieth S, Kemp W, Gow P, Fink M, Lubel J, Nicoll A, Gazzola A, Hong T, Ryan M, Knight V, Dev AT, Sood S, Bell S, Paul E, Roberts SK

(2017), J Viral Hepat, 24(11), 982-9

DOI: 10.1111/jvh.12717

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials

Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ben-Ari Z, Foster GR, Agarwal K, Laursen AL, Gerstoft J, Gao W, Huang HC, Fitzgerald B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Zeng Z, Chen HL, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Esteban R

(2017), Lancet Gastroenterol Hepatol, 2(11), 805-13

DOI: 10.1016/S2468-1253(17)30159-0

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

BourliÀre M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de L»dinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S; POLARIS-1 and POLARIS-4 Investigators

(2017), N Engl J Med, 376(22), 2134-46

DOI: 10.1056/NEJMoa1613512

Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study

Lubel J, Strasser S, Stuart KA, Dore G, Thompson A, Pianko S, Bollipo S, Mitchell JL, Fragomeli V, Jones T, Chivers S, Gow P, Iser D, Levy M, Tse E, Gazzola A, Cheng W, Nazareth S, Galhenage S, Wade A, Weltman M, Wigg A, MacQuillan G, Sasadeusz J, George J, Zekry A, Roberts SK; Australian Liver Association Clinical Research Network (ALA CRN)

(2017), Antivir Ther, 22(8), 699-710

DOI: 10.3851/IMP3168

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

Polaris Observatory HCV Collaborators

(2017), Lancet Gastroenterol Hepatol, 2(3), 161-76

DOI: 10.1016/S2468-1253(16)30181-9

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, Borgia SM, Shafran SD, Workowski KA, Pearlman B, Hyland RH, Stamm LM, Svarovskaia E, Dvory-Sobol H, Zhu Y, Subramanian GM, Brainard DM, McHutchison JG, Brâu N, Berg T, Agarwal K, Bhandari BR, Davis M, Feld JJ, Dore GJ, Stedman CAM, Thompson AJ, Asselah T, Roberts SK, Foster GR

(2017), Gastroenterology, 153(1), 113-22

DOI: 10.1053/j.gastro.2017.03.047

Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy

Lim L, Thompson A, Patterson S, George J, Strasser S, Lee A, Sievert W, Nicoll A, Desmond P, Roberts S, Marion K, Bowden S, Locarnini S, Angus P

(2017), Liver Int, 37(6), 827-35

DOI: 10.1111/liv.13331

Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese

Ooi GJ, Burton PR, Doyle L, Wentworth JM, Bhathal PS, Sikaris K, Cowley MA, Roberts SK, Kemp W, O'Brien PE, Brown WA

(2017), Obes Surg, 27(1), 115-25

DOI: 10.1007/s11695-016-2246-5

Displacement of a power-injectable PICC following computed tomography pulmonary angiogram

Lee JTL, Ricketts J

(2017), Radiol Case Rep, 12(4), 690-2

DOI: 10.1016/j.radcr.2017.07.016

The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting

Rademaker M, Gupta M, Andrews M, Armour K, Baker C, Foley P, Gebauer K, George J, Rubel D, Sullivan J

(2017), Australas J Dermatol, 58(3), 166-70

DOI: 10.1111/ajd.12521

Debunking the myth of wool allergy: reviewing the evidence for immune and non-immune cutaneous reactions

Zallmann M, Smith PK, Tang MLK, Spelman LJ, Cahill JL, Wortmann G, Katelaris CH, Allen KJ, Su JC

(2017), Acta Derm Venereol, 97(8), 906-15

DOI: 10.2340/00015555-2655

Keratoacanthoma formation after skin grafting: a brief report and pathophysiological hypothesis

Lee S, Coutts I, Ryan A, Stavrakoglou A

(2017), Australas J Dermatol, 58(3), e117-9

DOI: 10.1111/ajd.12501